Results 101 to 110 of about 214,341 (267)

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias.
Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim, Ji Sun Chun, Borim Lee, Miso Kim, Kwangsoo Kim, Byung Kwan Choi, Jeongmin Seo, Jin Hyoung Kang, Taehoon Ko, In‐Wha Kim, Jung Mi Oh   +13 more
wiley   +1 more source

Utility of Fine Needle Aspiration Supernatant for Real‐Time PCR–Based Mutation Analysis in Non–Small Cell Lung Cancer

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background The emergence of personalized therapy and molecular sequencing has significantly transformed the management of advanced non–small cell lung carcinoma (NSCLC). Supernatants obtained from fine needle aspiration (FNA) have been shown to be a reliable source of high‐quality nucleic acid for molecular testing.
Adeyinka Akinsanya, Riley Gorden, Madison Rector, Hamna Muhammad, Melissa Randolph, Matt Sperling, Kemin Xu, Sheila Segura, Omer Saeed, Tieying Hou   +9 more
wiley   +1 more source

Risk–Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
The therapeutic status of drug administration in phase 2 cancer trials is ambiguous, as these studies test efficacy without strong evidence of clinical benefit. Nonetheless, patients face meaningful risks. This review compared efficacy and safety of monotherapy drugs in phase 2 and phase 3 trials across six cancer types.
Charlotte Ouimet, Monica Rosu, Jonathan Kimmelman   +2 more
wiley   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, EarlyView.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

Lung Cancer Patients Display Increased Expression of Bovine Meat and Milk Factor (BMMF) Proteins in Peritumor Alveolar Macrophages

International Journal of Cancer, EarlyView.
Plasmid‐like DNA sequences frequently found in bovine milk and serum have been proposed as infectious agents promoting indirect carcinogenesis. This multi‐omics study detected immune cells positive for these bovine meat and milk factors (BMMFs) in patients with lung cancer, with BMMF expression inversely correlated with smoking intensity.
Nives Cecere, Kristina Alikhanyan, Claudia Ernst, Lisa Häfele, Lars Feuerbach, Imke Grewe, Sumen Siqin, Karin Gunst, Gunjan Shukla, Veronika Frehtman, Claudia Tessmer, Florian Eichhorn, Michael Allgäuer, Alexander Brobeil, Ilse Hofmann, Barbara Leuchs, Marc A. Schneider, Timo Bund   +17 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

International Journal of Cancer, EarlyView.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva, Jacopo Bellomo, Meltem Gönel, Vittorio Stumpo, Victor Egon Staartjes, Flavio Vasella, Kevin Akeret, André Sagerer, Anna Maria Zeitlberger, David Wasilewski, Christopher Krämer, Sven König, Julia Onken, Tareq Juratli, Alexander Köpp, Regina Reimann, Marcus Czabanka, Peter Vajkoczy, Ilker Y. Eyüpoglu, Oliver Bozinov, Michael Weller, Emilie Le Rhun, Luca Regli, Carlo Serra, Marian C. Neidert, Stefanos Voglis   +25 more
wiley   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, EarlyView.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

International Journal of Cancer, EarlyView.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas   +7 more
wiley   +1 more source